주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기
통합검색
로그인
고객센터
주요메뉴
질환포커스
세계의약뉴스
국내의약뉴스
성상변경내역
약제급여기준 개정내역
제약업계 소식
메디컬포커스
컨퍼런스
CME
근골격계
남성건강
내분비대사계
면역계
비뇨기계
뇌심혈관계
종양
호흡기계
감각기관계
중추신경계
소화기계
감염계
혈액 및 조혈계
미용
기타
최근 해외학술대회의 주요 발표내용을 제공합니다.
컨퍼런스 커버리지
2025 San Antonio Breast Cancer Symposium (SABCS 2025)
09 December - 12 December, 2025, United States
5-year data back omission of sentinel lymph node biopsy in early-stage breast cancer
2026-02-04
Sentinel lymph node biopsy (SLNB) may be safely omitted after breast-conserving therapy in patients with early-stage, node-negative breast cancer, with 5-year data from the BOOG 13-08 trial showing no difference in regional recurrence-free and distant disease-free survival outcomes whether or not SLNB was performed.
Sacituzumab govitecan proves real-world survival benefits in metastatic breast cancer
2026-02-04
A real-world study of the antibody-drug conjugate (ADC) sacituzumab govitecan in patients with HR+/ HER2- metastatic breast cancer (mBC) or metastatic triple-negative
breast cancer
(mTNBC) shows consistent survival outcomes as those seen in clinical trials.
Cruciferous veggies protective against breast cancer?
2026-02-04
An analysis using data from two large prospective studies demonstrates the protective effect of cruciferous vegetable consumption against
breast cancer
.
No rise in breast cancer risk for young BRCA carriers on menopausal hormone therapy
2026-02-04
For young women with a pathogenic variant in BRCA1 or BRCA2, initiating hormone replacement therapy following surgical menopause does not appear to significantly increase the risk of breast cancer, with oestrogen-alone therapy even conferring protection, according to a study.
Use of sacituzumab govitecan safe, efficacious in pretreated metastatic breast cancer
2026-02-04
A recent China study has provided further evidence on the real-world efficacy and safety of sacituzumab govitecan (SG) in HR+/HER2- and triple-negative
breast cancer
(TNBC) patients who have received at least three lines of prior therapy.
EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2? ABC
2026-02-04
In the phase III EPIK-B5 study, adding alpelisib, an α-specific PI3K inhibitor, to fulvestrant improves progression-free survival (PFS) in men and postmenopausal women with HR+, HER2− advanced
breast cancer
(ABC) harbouring a
PIK3CA
mutation who have progressed on or after treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).
1
최근 본 콘텐츠
최근 본 콘텐츠가 없습니다
관심제품
관심콘텐츠
